Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Stock Rated “Moderate Buy” by Sell-Side Analysts

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $56.38.

Several research firms have recently weighed in on IMCR. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a report on Monday, August 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Immunocore in a research report on Friday, August 21st. They set an “overweight” rating and a $50.00 price objective on the stock.

Immunocore Stock Down 0.3%

Shares of Immunocore stock opened at $30.64 on Tuesday. Immunocore has a one year low of $27.56 and a one year high of $40.71. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. The stock’s 50-day moving average is $34.37 and its 200 day moving average is $31.72. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -82.81 and a beta of 0.74.

Immunocore (NASDAQ:IMCR) last released its earnings results on Friday, August 7th. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. Equities research analysts anticipate that Immunocore will post 0.06 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IMCR. Engineers Gate Manager LP boosted its holdings in Immunocore by 334.3% in the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after acquiring an additional 46,435 shares in the last quarter. denkapparat Operations GmbH acquired a new position in shares of Immunocore during the second quarter worth approximately $209,000. Braidwell LP bought a new position in shares of Immunocore in the 2nd quarter worth $16,552,000. Headlands Technologies LLC bought a new position in shares of Immunocore in the 2nd quarter worth $290,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Immunocore in the 2nd quarter valued at $2,145,000. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells.

The company’s lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients.